$PRTO - RA Capital Management and Deerfield hold biggest positions. Baker bros and Perceptive Advisors have stakes too.
Upcoming Catalyst From Recent Quaterly report "We made important progress in our Phase 3 clinical program evaluating vonapanitase, and we remain on track to report top-line data from our first Phase 3 study, PATENCY-1, this December,” said Timothy Noyes, President and Chief Executive Officer of Proteon. “Physician and patient interest in the vonapanitase program remains high, and we continue to expect to complete enrollment in our second Phase 3 study, PATENCY-2, in the first quarter of 2017. Our cash position will fund operations into the fourth quarter of 2017, a year beyond our expected announcement of PATENCY-1 results.”
Low floater. In the $8-9 range for a few weeks, Moved up from the $5-6 range in late June when somebody bought a huge load of shares...seems to want to go even higher now.
